WO2023162995A1 - 新規セレンテラジン誘導体 - Google Patents
新規セレンテラジン誘導体 Download PDFInfo
- Publication number
- WO2023162995A1 WO2023162995A1 PCT/JP2023/006307 JP2023006307W WO2023162995A1 WO 2023162995 A1 WO2023162995 A1 WO 2023162995A1 JP 2023006307 W JP2023006307 W JP 2023006307W WO 2023162995 A1 WO2023162995 A1 WO 2023162995A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- general formula
- carbon atoms
- represented
- hydrocarbon group
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
Definitions
- the present invention relates to novel coelenterazine derivatives.
- In vivo molecular event visualization technology is an indispensable technology for the diagnosis of various diseases and the development of therapeutic methods.
- Visualization techniques using bioluminescence are the mainstream of visualization techniques for in vivo molecular events, and techniques that apply the luminescence systems of fireflies and marine organisms have been developed.
- the luminescence system of marine organisms has attracted attention due to its high luminescence brightness, the small molecular weight of luciferase, and the simplicity of the luminescence system. It is preferably used.
- nCTZ natural coelenterazine
- nCTZ natural coelenterazine
- an object of the present invention is to solve the above-described problems of the prior art and to provide a novel coelenterazine derivative having high luminescence brightness and enzyme specificity.
- Another object of the present invention is to provide a novel coelenterazine derivative that exhibits high luminescence intensity, emits light on the long wavelength side, and has enzyme specificity.
- R 1 represents the following general formula (1-1-1), (1-1-2), (1-1-3) or (1-1-4): wherein R 1-1 is a hydrocarbon group having 1 to 4 carbon atoms, R 1-2 is each independently hydrogen or a hydrocarbon group having 1 to 3 carbon atoms, and m is an integer from 2 to 8, R 2 is represented by —R 2′ or —CH 2 —R 2′ , where R 2′ is represented by the following general formulas (1-2-1), (1-2-2), (1- 2-3), (1-2-4) or (1-2-5): wherein R 2-1 is hydrogen, halogen, —N(R 2-1-1 ) 2 or —OR 2-1-1 (wherein R 2-1-1 is are each independently hydrogen or a hydrocarbon group having 1 to 3 carbon atoms.), R 2-2 is a hydrocarbon group having 1 to 4 carbon atoms, and R 2-3 is each independently hydrogen or a hydrocarbon group having 1 to 3 carbon
- R 4 is hydrogen, -(CH 2 ) n -OR 4-1 , -N(R 4-1 ) 2 or -CF 3 , wherein R 4-1 is , each independently hydrogen or a hydrocarbon group having 1 to 3 carbon atoms, n is an integer of 0 to 3,
- R 5 is the following general formula (2-5-1), (2-5-2), (2-5-3), (2-5-4) or (2-5-5): wherein R 5-1 is hydrogen, halogen, —N(R 5-1-1 ) 2 or —OH (wherein R 5-1-1 is each independently hydrogen or a hydrocarbon group having 1 to 3 carbon atoms.), R 5-2 is a hydrocarbon group having 1 to 4 carbon atoms, and R 5-3 is each independently hydrogen or 1 to 3 carbon atoms.
- Such a coelenterazine derivative of the present invention has high luminescence brightness and enzyme specificity.
- the coelenterazine derivative of the present invention is represented by the above general formula (1), and R 1 is represented by the above general formula (1-1-3). In this case, the emission luminance is improved.
- the coelenterazine derivative of the present invention is represented by general formula (1) above, wherein R 2 is represented by —CH 2 —R 2′ , wherein R 2′ is represented by general formula (1-2-1) above. is preferably represented by Also in this case, the light emission luminance is improved.
- the coelenterazine derivative of the present invention is represented by the above general formula (1) and R 3 is represented by the above general formula (1-3-2). Also in this case, the light emission luminance is improved.
- the coelenterazine derivative of the present invention has the following structural formula (1-1): It is particularly preferred to be represented by In this case, the luminance of light emitted from the light-emitting system using the coelenterazine derivative is particularly high.
- the coelenterazine derivative of the present invention is preferably represented by the above general formula (2), and R 4 is preferably represented by —(CH 2 ) n —OR 4-1 . In this case, the emission luminance is improved.
- the coelenterazine derivative of the present invention is preferably represented by the above general formula (2), and R 5 is preferably represented by the above general formula (2-5-1). Also in this case, the light emission luminance is improved.
- the coelenterazine derivative of the present invention is preferably represented by the above general formula (2), and R 6 is hydrogen. Also in this case, the light emission luminance is improved.
- the coelenterazine derivative of the present invention has the following structural formula (2-1) or (2-2): It is particularly preferred to be represented by In this case, the luminance of light emitted from the light-emitting system using the coelenterazine derivative is particularly high.
- 1 is a graph showing the luminescence intensity of each luminescent substrate in living cells when ALuc16 is used as a luciferase.
- 1 is a graph showing the luminescence intensity of each luminescent substrate in a lysate when ALuc16 is used as a luminescent enzyme. It is an emission spectrum of each luminescent substrate when ALuc16 is used as a luminescent enzyme.
- 1 is a graph showing the luminescence intensity of each luminescent substrate in living cells when ALuc47 is used as a luciferase.
- 1 is a graph showing the luminescence intensity of each luminescent substrate in a lysate when ALuc47 is used as a luminescent enzyme.
- each luminescent substrate when ALuc47 is used as a luminescent enzyme.
- 4 is a graph showing the luminescence intensity of each luminescent substrate in living cells when RLuc8.6SG is used as a luciferase.
- 4 is a graph showing the luminescence intensity of each luminescent substrate in a lysate when RLuc8.6SG is used as a luciferase.
- It is an emission spectrum of each luminescent substrate when RLuc8.6SG is used as a luminescent enzyme.
- 1 is a graph showing the luminescence intensity of each luminescent substrate in living cells when NanoLuc is used as a luminescent enzyme.
- 1 is a graph showing the luminescence intensity of each luminescent substrate in a lysate when NanoLuc is used as a luminescent enzyme. It is an emission spectrum of each luminescent substrate when NanoLuc is used as a luminescent enzyme.
- the coelenterazine derivative of the present invention is characterized by being represented by the above general formula (1) or (2).
- the coelenterazine derivative of the present invention differs from the natural coelenterazine (nCTZ) in that the hydroxyphenyl group at the 6-position of the imidazopyrazinone skeleton is converted to a bicyclic structure containing oxygen or nitrogen [general formula (1 )], or differs from the natural coelenterazine in that the methylene group in the benzyl group at the 8-position is converted to a thioether [general formula (2)], and based on the difference in chemical structure, the natural coelenterazine It has a different enzymatic specificity than coelenterazine.
- the coelenterazine derivative of the present invention has an enzyme specificity different from that of the natural coelenterazine, but a decrease in luminescence brightness is suppressed, and luminescence brightness sufficient for in vivo imaging is maintained. It can be used as a luminescent substrate in a luminescent system derived from marine organisms.
- the mechanism of luminescence using the coelenterazine derivative of the present invention as a luminescence substrate is not particularly limited. Protonated to the anionic state, followed by one electron transfer to triplet oxygen, radical coupling to form a peroxide anion, which cyclizes to form a dioxetanone intermediate, which decomposes It is believed that decarboxylation produces amidopyrazine in a singlet excited state, which transitions to the ground state and emits light.
- Coelenterazine derivative represented by general formula (1) The coelenterazine derivative of the first embodiment of the present invention is represented by the following general formula (1).
- R 1 is represented by the following general formula (1-1-1), (1-1-2), (1-1-3) or (1-1-4): is represented by In general formula (1-1-1), (1-1-2), (1-1-3) or (1-1-4) for the 6-position of the imidazopyrazinone skeleton in general formula (1) is not particularly limited.
- R 1-1 is a hydrocarbon group having 1 to 4 carbon atoms (particularly, a carbon chain)
- R 1-2 is each independently hydrogen or carbon It is a hydrocarbon group of numbers 1 to 3, and m is an integer of 2 to 8 (especially an even number).
- R 1-1 in general formula (1-1-4) above is a hydrocarbon group having 1 to 4 carbon atoms
- the group represented by general formula (1-1-4) is a benzene ring. It has a structure in which 4- to 7-membered rings are condensed.
- R 1-1 is preferably a straight chain hydrocarbon group having 1 to 4 carbon atoms.
- a hydrocarbon group having 1 to 4 carbon atoms as R 1-1 is bound to m (2 to 8) substituents R 1-2 , that is, R 1-1 is a carbon It is a 4- to 10-valent hydrocarbon group having a number of 1 to 4.
- the substituent R 1-2 replaces the hydrogen of the hydrocarbon group.
- the hydrocarbon group having 1 to 4 carbon atoms as R 1-1 may be saturated or unsaturated.
- R 1-1 is a hydrocarbon group having 1 carbon atom (when R 1-1 forms a 4-membered ring together with N and a benzene ring)
- m is preferably 2.
- the tetravalent hydrocarbon group having 1 carbon atom include a methane-tetrayl group.
- m is preferably 2 or 4 when R 1-1 is a hydrocarbon group having 2 carbon atoms (when R 1-1 forms a 5-membered ring together with N and a benzene ring). In this case, R 1-1 can be saturated or unsaturated.
- m is 4 when R 1-1 is saturated and m is 2 when R 1-1 is unsaturated.
- examples of the tetravalent hydrocarbon group (carbon chain) having 2 carbon atoms include ethene-tetrayl group, and examples of the hexavalent hydrocarbon group (carbon chain) having 2 carbon atoms include ethane-hexayl group.
- R 1-1 is a hydrocarbon group having 3 carbon atoms (when R 1-1 forms a six-membered ring together with N and a benzene ring), m is preferably 2, 4 or 6. In this case, R 1-1 can be saturated or unsaturated.
- R 1-1 When R 1-1 is saturated, m is preferably 6, and when R 1-1 is unsaturated, m is preferably 4 or 2.
- the tetravalent hydrocarbon group having 3 carbon atoms (carbon chain) includes propyne-tetrayl group, and the hexavalent hydrocarbon group having 3 carbon atoms (carbon chain) includes propene-hexayl group, Examples of the octavalent hydrocarbon group (carbon chain) having 3 carbon atoms include a propane-octyl group.
- R 1-1 when R 1-1 is a hydrocarbon group having 4 carbon atoms (when R 1-1 forms a seven-membered ring together with N and a benzene ring), m may be 2, 4, 6 or 8. preferable.
- R 1-1 can be saturated or unsaturated.
- m is preferably 8, and when R 1-1 is unsaturated, m is preferably 6, 4 or 2.
- the hexavalent hydrocarbon group having 4 carbon atoms (carbon chain) include butadiene-hexayl group
- examples of the octavalent hydrocarbon group having 4 carbon atoms (carbon chain) include butene-octyl group
- Examples of the decavalent hydrocarbon group having 4 carbon atoms include a butane-decyl group.
- R 1-2 in the above general formula (1-1-4) is each independently hydrogen or a hydrocarbon group having 1 to 3 carbon atoms, and the hydrocarbon group having 1 to 3 carbon atoms is Examples include an alkyl group having 1 to 3 carbon atoms and an alkenyl group having 2 to 3 carbon atoms.
- the alkyl group having 1 to 3 carbon atoms includes methyl group, ethyl group, n-propyl group and isopropyl group.
- alkenyl groups having 2 to 3 carbon atoms include vinyl groups and allyl groups.
- R 1 in general formula (1) above is preferably represented by general formula (1-1-3) above.
- R 1 in general formula (1) is represented by general formula (1-1-3) above, the emission luminance is improved.
- R 2 is represented by —R 2′ or —CH 2 —R 2′ , where R 2′ is represented by general formulas (1-2-1), (1- 2-2), (1-2-3), (1-2-4) or (1-2-5): is represented by general formula (1-2-1), (1-2-2), (1-2-3), (1-2-4) or The binding site of the benzene ring in (1-2-5) is not particularly limited.
- R 2-1 is hydrogen, halogen, —N(R 2-1-1 ) 2 or —OR 2-1-1 , where R 2- 1-1 are each independently hydrogen or a hydrocarbon group having 1 to 3 carbon atoms.
- R 2-2 is a hydrocarbon group having 1 to 4 carbon atoms (especially a carbon chain), and R 2-3 is each independently hydrogen or carbon It is a hydrocarbon group of numbers 1 to 3, and m is an integer of 2 to 8 (especially an even number).
- Halogen for R 2-1 in the general formula (1-2-1) includes fluorine, chlorine, bromine and the like.
- each R 2-1-1 is independently hydrogen or a hydrocarbon having 1 to 3 carbon atoms is the base.
- the hydrocarbon group having 1 to 3 carbon atoms include an alkyl group having 1 to 3 carbon atoms and an alkenyl group having 2 to 3 carbon atoms.
- the alkyl group having 1 to 3 carbon atoms includes methyl group, ethyl group, n-propyl group and isopropyl group.
- alkenyl groups having 2 to 3 carbon atoms include vinyl groups and allyl groups.
- R 2-2 in general formula (1-2-5) above is a hydrocarbon group having 1 to 4 carbon atoms
- the group represented by general formula (1-2-5) is a benzene ring. It has a structure in which 4- to 7-membered rings are condensed.
- R 2-2 is preferably a straight chain hydrocarbon group having 1 to 4 carbon atoms.
- a hydrocarbon group having 1 to 4 carbon atoms as R 2-2 is bound to m (2 to 8) substituents R 2-3 , that is, R 2-2 is a carbon It is a 4- to 10-valent hydrocarbon group having a number of 1 to 4.
- Substituents R 2-3 replace hydrogen in the hydrocarbon group.
- the hydrocarbon group having 1 to 4 carbon atoms as R 2-2 may be saturated or unsaturated.
- R 2-2 is a hydrocarbon group having 1 carbon atom (when R 2-2 forms a 4-membered ring together with N and a benzene ring), m is preferably 2.
- the tetravalent hydrocarbon group having 1 carbon atom include a methane-tetrayl group.
- R 2-2 is a hydrocarbon group having 2 carbon atoms (when R 2-2 forms a 5-membered ring together with N and a benzene ring), m is preferably 2 or 4.
- R 2-2 can be saturated or unsaturated.
- m is 4 when R 2-2 is saturated and m is 2 when R 2-2 is unsaturated.
- Examples of the tetravalent hydrocarbon group having 2 carbon atoms (carbon chain) include ethene-tetrayl group, and examples of the hexavalent hydrocarbon group having 2 carbon atoms include ethane-hexayl group.
- R 2-2 is a hydrocarbon group having 3 carbon atoms (when R 2-2 forms a six-membered ring together with N and a benzene ring), m is preferably 2, 4 or 6. In this case, R 2-2 can be saturated or unsaturated. When R 2-2 is saturated, m is preferably 6, and when R 2-2 is unsaturated, m is preferably 4 or 2.
- the tetravalent hydrocarbon group having 3 carbon atoms (carbon chain) includes propyne-tetrayl group
- the hexavalent hydrocarbon group having 3 carbon atoms (carbon chain) includes propene-hexayl group
- Examples of the octavalent hydrocarbon group (carbon chain) having 3 carbon atoms include a propane-octyl group.
- R 2-2 is a hydrocarbon group having 4 carbon atoms (when R 2-2 forms a seven-membered ring together with N and a benzene ring)
- m may be 2, 4, 6 or 8. preferable. In this case, R 2-2 can be saturated or unsaturated.
- m When R 2-2 is saturated, m is preferably 8, and when R 2-2 is unsaturated, m is preferably 6, 4 or 2.
- the hexavalent hydrocarbon group having 4 carbon atoms (carbon chain) include butadiene-hexayl group
- examples of the octavalent hydrocarbon group having 4 carbon atoms (carbon chain) include butene-octyl group
- Examples of the decavalent hydrocarbon group having 4 carbon atoms include a butane-decyl group.
- R 2-3 in the above general formula (1-2-5) is each independently hydrogen or a hydrocarbon group having 1 to 3 carbon atoms, and the hydrocarbon group having 1 to 3 carbon atoms is Examples include an alkyl group having 1 to 3 carbon atoms and an alkenyl group having 2 to 3 carbon atoms.
- the alkyl group having 1 to 3 carbon atoms includes methyl group, ethyl group, n-propyl group and isopropyl group.
- alkenyl groups having 2 to 3 carbon atoms include vinyl groups and allyl groups.
- R 2 in general formula (1) above is preferably represented by —CH 2 —R 2′
- R 2′ is preferably represented by general formula (1-2-1) above. preferably.
- luminance is improved.
- R 3 is the following general formula (1-3-1), (1-3-2) or (1-3-3): is represented by In general formula (1-3-2) above, R 3-1 is hydrogen or a hydrocarbon group having 1 to 3 carbon atoms.
- Examples of the hydrocarbon group having 1 to 3 carbon atoms for R 3-1 in the general formula (1-3-2) include an alkyl group having 1 to 3 carbon atoms and an alkenyl group having 2 to 3 carbon atoms. be done.
- the alkyl group having 1 to 3 carbon atoms includes methyl group, ethyl group, n-propyl group and isopropyl group.
- Examples of alkenyl groups having 2 to 3 carbon atoms include vinyl groups and allyl groups.
- R 3 in general formula (1) above is preferably represented by general formula (1-3-2) above.
- R 3 in general formula (1) is represented by general formula (1-3-2) above, luminance is improved.
- R 3-1 in general formula (1-3-2) above is preferably hydrogen.
- R 3 in general formula (1) is represented by general formula (1-3-2) above and R 3-1 is hydrogen, luminance is further improved.
- the coelenterazine derivative of the present invention has the following structural formula (1-1): It is particularly preferred to be represented by In this case, the luminance of light emitted from the light-emitting system using the coelenterazine derivative is particularly high.
- Coelenterazine derivative represented by general formula (2) A coelenterazine derivative according to a second embodiment of the present invention is represented by the following general formula (2).
- R 4 is hydrogen, —(CH 2 ) n —OR 4-1 , —N(R 4-1 ) 2 or —CF 3 , where R 4-1 is , are each independently hydrogen or a hydrocarbon group having 1 to 3 carbon atoms, and n is an integer of 0 to 3.
- the bonding position of R 4 to the benzene ring bonded to the 6-position of the imidazopyrazinone skeleton in general formula (2) may be o-, m-, or p-.
- each R 4-1 is independently hydrogen or a hydrocarbon group having 1 to 3 carbon atoms. be.
- examples of the hydrocarbon group having 1 to 3 carbon atoms include an alkyl group having 1 to 3 carbon atoms and an alkenyl group having 2 to 3 carbon atoms.
- the alkyl group having 1 to 3 carbon atoms includes methyl group, ethyl group, n-propyl group and isopropyl group.
- alkenyl groups having 2 to 3 carbon atoms include vinyl groups and allyl groups.
- R 4 in general formula (2) above is preferably represented by —(CH 2 ) n —OR 4-1 .
- R 4 in general formula (2) is represented by —(CH 2 ) n —OR 4-1 , luminance is improved.
- n in —(CH 2 ) n —OR 4-1 is preferably 0, and R 4-1 is preferably hydrogen. That is, R 4 in general formula (2) above is particularly preferably —OH. When R 4 in general formula (2) is —OH, luminance is further improved.
- R 5 is the following general formula (2-5-1), (2-5-2), (2-5-3), (2-5-4) or (2- 5-5): is represented by General formula (2-5-1), (2-5-2), (2-5-3), (2-5-4) or (2-5-5) for S in general formula (2) ) is not particularly limited.
- R 5-1 is hydrogen, halogen, —N(R 5-1-1 ) 2 or —OH, wherein R 5-1-1 is Each independently represents hydrogen or a hydrocarbon group having 1 to 3 carbon atoms.
- R 5-2 is a hydrocarbon group having 1 to 4 carbon atoms (particularly, a carbon chain), and R 5-3 is each independently hydrogen or carbon It is a hydrocarbon group of numbers 1 to 3, and m is an integer of 2 to 8 (especially an even number).
- Halogen for R 5-1 in the general formula (2-5-1) includes fluorine, chlorine, bromine and the like.
- each R 5-1-1 is independently hydrogen or a hydrocarbon group having 1 to 3 carbon atoms.
- the hydrocarbon group having 1 to 3 carbon atoms include an alkyl group having 1 to 3 carbon atoms and an alkenyl group having 2 to 3 carbon atoms.
- the alkyl group having 1 to 3 carbon atoms includes methyl group, ethyl group, n-propyl group and isopropyl group.
- alkenyl groups having 2 to 3 carbon atoms include vinyl groups and allyl groups.
- R 5-2 in the above general formula (2-5-5) is a hydrocarbon group having 1 to 4 carbon atoms
- the group represented by general formula (2-5-5) is a benzene ring. It has a structure in which 4- to 7-membered rings are condensed.
- R 5-2 is preferably a straight chain hydrocarbon group having 1 to 4 carbon atoms.
- a hydrocarbon group having 1 to 4 carbon atoms as R 5-2 is bound to m (2 to 8) substituents R 5-3 , that is, R 5-2 is a carbon It is a 4- to 10-valent hydrocarbon group having a number of 1 to 4.
- the substituent R 5-3 replaces hydrogen in the hydrocarbon group.
- the hydrocarbon group having 1 to 4 carbon atoms as R 5-2 may be saturated or unsaturated.
- R 5-2 is a hydrocarbon group having 1 carbon atom (when R 5-2 forms a 4-membered ring together with N and a benzene ring)
- m is preferably 2.
- the tetravalent hydrocarbon group having 1 carbon atom include a methane-tetrayl group.
- m is preferably 2 or 4 when R 5-2 is a hydrocarbon group having 2 carbon atoms (when R 5-2 forms a 5-membered ring together with N and a benzene ring). In this case, R 5-2 can be saturated or unsaturated.
- m is preferably 4 when R 5-2 is saturated and m is 2 when R 2-2 is unsaturated.
- examples of the tetravalent hydrocarbon group having 2 carbon atoms (carbon chain) include ethene-tetrayl group, and examples of the hexavalent hydrocarbon group having 2 carbon atoms include ethane-hexayl group.
- R 5-2 is a hydrocarbon group having 3 carbon atoms (when R 5-2 forms a six-membered ring together with N and a benzene ring), m is preferably 2, 4 or 6. In this case, R 5-2 can be saturated or unsaturated.
- R 5-2 When R 5-2 is saturated, m is preferably 6, and when R 5-2 is unsaturated, m is preferably 4 or 2.
- the tetravalent hydrocarbon group having 3 carbon atoms (carbon chain) includes propyne-tetrayl group, and the hexavalent hydrocarbon group having 3 carbon atoms (carbon chain) includes propene-hexayl group, Examples of the octavalent hydrocarbon group (carbon chain) having 3 carbon atoms include a propane-octyl group.
- R 5-2 when R 5-2 is a hydrocarbon group having 4 carbon atoms (when R 5-2 forms a seven-membered ring together with N and a benzene ring), m may be 2, 4, 6 or 8. preferable.
- R 5-2 can be saturated or unsaturated.
- m is preferably 8, and when R 5-2 is unsaturated, m is preferably 6, 4 or 2.
- the hexavalent hydrocarbon group having 4 carbon atoms (carbon chain) include butadiene-hexayl group
- examples of the octavalent hydrocarbon group having 4 carbon atoms (carbon chain) include butene-octyl group
- Examples of the decavalent hydrocarbon group having 4 carbon atoms include a butane-decyl group.
- R 5-3 in the above general formula (2-5-5) is each independently hydrogen or a hydrocarbon group having 1 to 3 carbon atoms, and the hydrocarbon group having 1 to 3 carbon atoms is Examples include an alkyl group having 1 to 3 carbon atoms and an alkenyl group having 2 to 3 carbon atoms.
- the alkyl group having 1 to 3 carbon atoms includes methyl group, ethyl group, n-propyl group and isopropyl group.
- alkenyl groups having 2 to 3 carbon atoms include vinyl groups and allyl groups.
- R 5 in general formula (2) above is preferably represented by general formula (2-5-1) above.
- luminance is improved.
- R 5-1 in general formula (2-5-1) above is preferably hydrogen or halogen, more preferably hydrogen or fluorine.
- R 5 in general formula (2) is represented by general formula (2-5-1) and R 5-1 is hydrogen or halogen, the luminance is further improved, and R 5-1 is hydrogen or fluorine. In the case of , the emission luminance is further improved.
- R 6 is hydrogen or a hydrocarbon group having 1 to 3 carbon atoms.
- hydrocarbon groups having 1 to 3 carbon atoms include alkyl groups having 1 to 3 carbon atoms and alkenyl groups having 2 to 3 carbon atoms.
- the alkyl group having 1 to 3 carbon atoms includes methyl group, ethyl group, n-propyl group and isopropyl group.
- alkenyl groups having 2 to 3 carbon atoms include vinyl groups and allyl groups.
- R 6 in the general formula (2) is preferably hydrogen.
- R 6 in general formula (2) is hydrogen, the luminance is improved.
- the coelenterazine derivative of the present invention has the following structural formula (2-1) or (2-2): It is particularly preferred to be represented by In this case, the luminance of light emitted from the light-emitting system using the coelenterazine derivative is particularly high.
- the coelenterazine derivative represented by the general formula (1) is not particularly limited, but can be synthesized, for example, as follows.
- a benzyl compound is synthesized by a coupling reaction using 2-amino-3,5-dibromoaminopyrazine, benzylmagnesium chloride and bis(triphenylphosphine)palladium(II) dichloride.
- Suzuki-Miyaura coupling is performed using the benzyl compound and boronic acid to synthesize a benzyl compound having a desired ring structure introduced at the 6-position.
- the coelenterazine derivative represented by the general formula (2) is not particularly limited, but can be synthesized, for example, as follows.
- the 8-brominated intermediate and thiol are subjected to a substitution reaction with sodium hydride to synthesize a thiol.
- the thiol form and boron tribromide may be reacted for demethylation.
- the coelenterazine derivative represented by the general formula (2) which is the desired substance, can be synthesized by condensing the thiol form with the ketoacetal form.
- the coelenterazine derivative of the present invention emits light through an oxidation reaction catalyzed by a marine bioluminescent enzyme. Therefore, the coelenterazine derivative of the present invention can be used as a luminescent label in biological measurement/detection, and can be used, for example, to label amino acids, polypeptides, proteins, nucleic acids, and the like. Methods for binding the coelenterazine derivative of the present invention to these substances are well known to those skilled in the art. Coelenterazine derivatives of the invention can be conjugated.
- the coelenterazine derivative of the present invention can also be used for measurement/detection using detection of marine bioluminescent enzyme activity by luminescence of a luminescent substrate.
- the coelenterazine derivative of the present invention can also be used for measurement/detection using detection of marine bioluminescent enzyme activity by luminescence of a luminescent substrate.
- the coelenterazine derivative of the present invention by administering the coelenterazine derivative of the present invention to cells or animals into which a marine bioluminescent enzyme gene has been introduced, the in vivo expression of a target gene or protein can be measured/detected.
- the coelenterazine derivative represented by the above general formula (2) can emit longer wavelength light than natural coelenterazine, and the longer wavelength light is transmitted in vivo. Because of its high efficiency, it is useful as a labeling material for visualizing lesions deep inside the body.
- luciferase When the coelenterazine derivative of the present invention is used as a luminescent substrate (luciferin), either natural or artificial luminescent enzyme (luciferase) can be used.
- Natural luminescent enzymes include luciferase (RLuc) from Renilla reniformis, luciferase (Gluc) from Gaussia princeps, luciferase (Oluc) from luminescent shrimp (Oplophorus gracilirostris), and luciferase from sea cactus. etc.
- Examples of the artificial luminescent enzyme include "NanoLuc” manufactured by Promega, which is an artificial luminescent enzyme derived from luminescent shrimp (Oplophorus gracilirostris), and Renilla luciferase 8.6-, which is an artificial luminescent enzyme derived from sea pansy (Renilla reniformis). 535SG (RLuc8.6SG), and ALuc, which is a group of artificial luciferases derived from luminous plankton developed by Dr. Seungbae Kim et al. of the National Institute of Advanced Industrial Science and Technology.
- ALuc includes various artificial luciferases, such as ALuc16, ALuc47, and ALuc49.
- the coelenterazine derivative of the present invention has luciferase specificity, and the luminescence brightness varies greatly depending on the enzyme. Therefore, according to the coelenterazine derivative of the present invention, it is possible to simultaneously visualize multiple in vivo phenomena such as molecular events occurring in vivo and cancer metastasis with high sensitivity and high speed. In the coexistence, it is possible to make only a specific luciferase luminous.
- these marine bioluminescent enzymes have the advantage that their molecular size is small, so that even if they are introduced into the body, the load on the body is small, and the expression efficiency is high when the gene is introduced into the body.
- the method of incorporating the gene capable of producing the marine bioluminescence enzyme into the living body is not particularly limited, and for example, a method using a vector can be used.
- Production of vectors encoding such marine bioluminescent enzymes is not particularly limited, either, and they can be produced by known methods.
- commercially available products can also be used.
- ⁇ R-luc8'', ⁇ R-luc8.6_547'' and the like manufactured by the company can also be used.
- TransIT-LT1 reagent manufactured by Mirus may be used to transiently express a plasmid encoding a marine organism-derived luciferase in living cells.
- the coelenterazine derivative of the present invention is preferably used as a solution.
- the solvent used for preparing the solution include alcohols such as methanol and ethanol in addition to water.
- the concentration of the coelenterazine derivative in the solution can be appropriately selected depending on the purpose, but is preferably in the range of 1 mM to 5 mM, for example.
- nCTZ natural substrate
- CTZh known natural analogous substrate 1
- DRC natural analogous substrate 2
- DLC natural analogous substrate 2
- Luminescence measurement in living cells and lysate cells A PerkinElmer IVIS imaging system (Caliper Life Sciences) was used for luminescence measurement.
- COS-7 cells derived from African green monkey kidney were used as live cells expressing luciferase, and lysate obtained by lysing the live cells was also evaluated.
- African green monkey kidney-derived COS-7 cells are seeded in 6-well microplates and cultured in a CO 2 incubator until they grow to fill 70% of the bottom area.
- TransIT-LT1 reagent (Mirus) is used to transiently express plasmids encoding the following marine organism-derived luciferases in each well cell.
- ALuc16 (ii) ALuc47 (iii) Renilla luciferase 8.6-535SG (RLuc8.6SG)
- NanoLuc After this lipofection, continue culturing in a CO2 incubator for 1 day. Each cell is then subcultured into a 96-well microplate and cultured for an additional day.
- each luminescent substrate was first dissolved in methanol (PEG400, 25%) to 5 mM (stock solution), and further diluted to 100 ⁇ M with phosphate-buffered saline (PBS) (hereinafter, diluted luminescence substrate solution).
- PBS phosphate-buffered saline
- This "diluted luminescent substrate solution” was previously dispensed into each well of an empty 96-well microplate.
- 40 ⁇ L of the “diluted luminescent substrate solution” was simultaneously injected into each well of the 96-well black frame microplate containing the aforementioned cell lysate.
- COS-7 cells are seeded in 6-well microplates and cultured in a CO 2 incubator until they grow to fill 70% of the bottom area.
- TransIT-LT1 reagent (Mirus) is used to transiently express plasmids encoding the following marine organism-derived luciferases in each well cell.
- ALuc16 (ii) ALuc47 (iii) Renilla luciferase 8.6-535SG (RLuc8.6SG)
- NanoLuc After this lipofection, continue culturing in a CO2 incubator for 1 day.
- the compound represented by the structural formula (2-1) exhibits luminescence activity with respect to ALuc16, RLuc8.6SG and NanoLuc. Ta. Further, as can be seen from FIGS. 3, 9 and 12, the compound represented by the structural formula (2-1) has emission spectra of 538 nm, 573 nm and 507 nm for ALuc16, RLuc8.6SG and NanoLuc, respectively. Indicated. Moreover, as can be seen from FIGS. 4 and 5, the compound represented by the structural formula (2-1) also exhibited luminescence with respect to ALuc47. Further, as can be seen from FIGS.
- the compound represented by the structural formula (2-2) exhibits luminescence activity with respect to ALuc16 and RLuc8.6SG. And as can be seen from FIG. 11, it showed slight luminescence for ALuc47 and NanoLuc. Thus, it was confirmed that the compound represented by Structural Formula (2-1) or (2-2) also has enzyme specificity. In addition, it was confirmed that the compound represented by the structural formula (2-1) or (2-2) has a longer emission wavelength by about 50 nm compared to natural selanterazine or the like.
- the coelenterazine derivative of the present invention can be used as a luminescent substrate for luciferases derived from marine organisms.
- it is widely used in various bioassays because it exhibits unique enzyme specificity, strong luminescence brightness, and long-wavelength luminescence characteristics.
- the long-wavelength-shifted emission properties facilitate the visualization of molecular events occurring deep within the body.
- it is brighter than the conventional one, it is possible to improve the detection sensitivity and detection limit of the bioassay.
- the luminescent substrate of this time exhibits luminescence specificity, it is possible to specifically detect a specific sample among a large number of samples. Such multiplexing dramatically increases the efficiency of bioassays and greatly contributes to the reduction of diagnostic costs.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
しかしながら、従来の海洋生物由来の発光システムにおいては、発光システムの発光輝度や発光酵素特異性を制御することが難しかった。
また、本発明は、発光輝度が高く、長波長側の発光を示し、酵素特異性を有する新規セレンテラジン誘導体を提供することを更なる課題とする。
R2は、-R2’又は-CH2-R2’で表され、ここで、R2’は、下記一般式(1-2-1)、(1-2-2)、(1-2-3)、(1-2-4)又は(1-2-5):
R3は、下記一般式(1-3-1)、(1-3-2)又は(1-3-3):
下記一般式(2):
R5は、下記一般式(2-5-1)、(2-5-2)、(2-5-3)、(2-5-4)又は(2-5-5):
R6は、水素又は炭素数1~3の炭化水素基である。]で表されることを特徴とする。
かかる本発明のセレンテラジン誘導体は、発光輝度が高く、酵素特異性を有する。
本発明のセレンテラジン誘導体は、上記一般式(1)又は(2)で表されることを特徴とする。
本発明のセレンテラジン誘導体は、天然型のセレンテラジン(nCTZ)に対して、イミダゾピラジノン骨格の6位のヒドロキシフェニル基が酸素又は窒素を含む二環式構造に変換されている点[一般式(1)]、又は、8位のベンジル基中のメチレン基がチオエーテルに変換されている点[一般式(2)]で、天然型のセレンテラジンと相違し、該化学構造の相違に基づき、天然型のセレンテラジンとは異なる酵素特異性を有する。
また、本発明のセレンテラジン誘導体は、天然型のセレンテラジンとは異なる酵素特異性を有しつつも、発光輝度の低下が抑制されており、生体内のイメージングに十分な発光輝度を保持しており、海洋生物由来の発光系における発光基質として利用できる。
上記一般式(1-1-4)中、R1-1は、炭素数1~4の炭化水素基(特には、炭素鎖)であり、R1-2は、それぞれ独立して水素又は炭素数1~3の炭化水素基であり、mは、2~8の整数(特には、偶数)である。
R1-1としての、炭素数1~4の炭化水素基には、m個(2~8個)の置換基R1-2が、結合しており、即ち、R1-1は、炭素数1~4の、4~10価の炭化水素基である。置換基R1-2は、炭化水素基の水素を置換するものである。また、R1-1としての、炭素数1~4の炭化水素基は、飽和であってもよいし、不飽和であってもよい。
R1-1が炭素数1の炭化水素基である場合(R1-1がN及びベンゼン環と共に4員環を形成する場合)、mは2であることが好ましい。炭素数1の4価の炭化水素基としては、メタン-テトライル基が挙げられる。
また、R1-1が炭素数2の炭化水素基である場合(R1-1がN及びベンゼン環と共に5員環を形成する場合)、mは2又は4であることが好ましい。この場合、R1-1は、飽和にも、不飽和にもなり得る。R1-1が飽和の場合、mは4であり、R1-1が不飽和の場合、mは2であることが好ましい。炭素数2の4価の炭化水素基(炭素鎖)としては、エテン-テトライル基が挙げられ、炭素数2の6価の炭化水素基(炭素鎖)としては、エタン-ヘキサイル基が挙げられる。
また、R1-1が炭素数3の炭化水素基である場合(R1-1がN及びベンゼン環と共に六員環を形成する場合)、mは2、4又は6であることが好ましい。この場合、R1-1は、飽和にも、不飽和にもなり得る。R1-1が飽和の場合、mは6であることが好ましく、R1-1が不飽和の場合、mは4又は2であることが好ましい。炭素数3の4価の炭化水素基(炭素鎖)としては、プロピン-テトライル基が挙げられ、炭素数3の6価の炭化水素基(炭素鎖)としては、プロペン-ヘキサイル基が挙げられ、炭素数3の8価の炭化水素基(炭素鎖)としては、プロパン-オクタイル基が挙げられる。
また、R1-1が炭素数4の炭化水素基である場合(R1-1がN及びベンゼン環と共に七員環を形成する場合)、mは2、4、6又は8であることが好ましい。この場合、R1-1は、飽和にも、不飽和にもなり得る。R1-1が飽和の場合、mは8であることが好ましく、R1-1が不飽和の場合、mは6、4又は2であることが好ましい。炭素数4の6価の炭化水素基(炭素鎖)としては、ブタジエン-ヘキサイル基が挙げられ、炭素数4の8価の炭化水素基(炭素鎖)としては、ブテン-オクタイル基が挙げられ、炭素数4の10価の炭化水素基としては、ブタン-デカイル基が挙げられる。
上記一般式(1-2-1)中、R2-1は、水素、ハロゲン、-N(R2-1-1)2又は-OR2-1-1であり、ここで、R2-1-1は、それぞれ独立して水素又は炭素数1~3の炭化水素基である。
上記一般式(1-2-5)中、R2-2は、炭素数1~4の炭化水素基(特には、炭素鎖)であり、R2-3は、それぞれ独立して水素又は炭素数1~3の炭化水素基であり、mは、2~8の整数(特には、偶数)である。
R2-1が-N(R2-1-1)2又は-OR2-1-1である場合、R2-1-1は、それぞれ独立して水素又は炭素数1~3の炭化水素基である。ここで、炭素数1~3の炭化水素基としては、炭素数1~3のアルキル基、炭素数2~3のアルケニル基等が挙げられる。炭素数1~3のアルキル基としては、メチル基、エチル基、n-プロピル基、イソプロピル基が挙げられる。炭素数2~3のアルケニル基としては、ビニル基、アリル基等が挙げられる。
R2-2としての、炭素数1~4の炭化水素基には、m個(2~8個)の置換基R2-3が、結合しており、即ち、R2-2は、炭素数1~4の、4~10価の炭化水素基である。置換基R2-3は、炭化水素基の水素を置換するものである。また、R2-2としての、炭素数1~4の炭化水素基は、飽和であってもよいし、不飽和であってもよい。
R2-2が炭素数1の炭化水素基である場合(R2-2がN及びベンゼン環と共に4員環を形成する場合)、mは2であることが好ましい。炭素数1の4価の炭化水素基としては、メタン-テトライル基が挙げられる。
また、R2-2が炭素数2の炭化水素基である場合(R2-2がN及びベンゼン環と共に5員環を形成する場合)、mは2又は4であることが好ましい。この場合、R2-2は、飽和にも、不飽和にもなり得る。R2-2が飽和の場合、mは4であることが好ましく、R2-2が不飽和の場合、mは2であることが好ましい。炭素数2の4価の炭化水素基(炭素鎖)としては、エテン-テトライル基が挙げられ、炭素数2の6価の炭化水素基としては、エタン-ヘキサイル基が挙げられる。
また、R2-2が炭素数3の炭化水素基である場合(R2-2がN及びベンゼン環と共に六員環を形成する場合)、mは2、4又は6であることが好ましい。この場合、R2-2は、飽和にも、不飽和にもなり得る。R2-2が飽和の場合、mは6であることが好ましく、R2-2が不飽和の場合、mは4又は2であることが好ましい。炭素数3の4価の炭化水素基(炭素鎖)としては、プロピン-テトライル基が挙げられ、炭素数3の6価の炭化水素基(炭素鎖)としては、プロペン-ヘキサイル基が挙げられ、炭素数3の8価の炭化水素基(炭素鎖)としては、プロパン-オクタイル基が挙げられる。
また、R2-2が炭素数4の炭化水素基である場合(R2-2がN及びベンゼン環と共に七員環を形成する場合)、mは2、4、6又は8であることが好ましい。この場合、R2-2は、飽和にも、不飽和にもなり得る。R2-2が飽和の場合、mは8であることが好ましく、R2-2が不飽和の場合、mは6、4又は2であることが好ましい。炭素数4の6価の炭化水素基(炭素鎖)としては、ブタジエン-ヘキサイル基が挙げられ、炭素数4の8価の炭化水素基(炭素鎖)としては、ブテン-オクタイル基が挙げられ、炭素数4の10価の炭化水素基としては、ブタン-デカイル基が挙げられる。
また、上記一般式(1-3-2)中のR3-1は、水素であることが好ましい。一般式(1)中のR3が上記一般式(1-3-2)で表され、R3-1が水素である場合、発光輝度が更に向上する。
R4が-(CH2)n-OR4-1又は-N(R4-1)2である場合、R4-1は、それぞれ独立して水素又は炭素数1~3の炭化水素基である。ここで、炭素数1~3の炭化水素基としては、炭素数1~3のアルキル基、炭素数2~3のアルケニル基等が挙げられる。炭素数1~3のアルキル基としては、メチル基、エチル基、n-プロピル基、イソプロピル基が挙げられる。炭素数2~3のアルケニル基としては、ビニル基、アリル基等が挙げられる。
また、-(CH2)n-OR4-1中のnは0であることが好ましく、R4-1は水素であることが好ましい。即ち、上記一般式(2)中のR4は、-OHであることが特に好ましい。一般式(2)中のR4が-OHである場合、発光輝度が更に向上する。
上記一般式(2-5-1)中、R5-1は、水素、ハロゲン、-N(R5-1-1)2又は-OHであり、ここで、R5-1-1は、それぞれ独立して水素又は炭素数1~3の炭化水素基である。
上記一般式(2-5-5)中、R5-2は、炭素数1~4の炭化水素基(特には、炭素鎖)であり、R5-3は、それぞれ独立して水素又は炭素数1~3の炭化水素基であり、mは、2~8の整数(特には、偶数)である。
R5-1が-N(R5-1-1)2である場合、R5-1-1は、それぞれ独立して水素又は炭素数1~3の炭化水素基である。ここで、炭素数1~3の炭化水素基としては、炭素数1~3のアルキル基、炭素数2~3のアルケニル基等が挙げられる。炭素数1~3のアルキル基としては、メチル基、エチル基、n-プロピル基、イソプロピル基が挙げられる。炭素数2~3のアルケニル基としては、ビニル基、アリル基等が挙げられる。
R5-2としての、炭素数1~4の炭化水素基には、m個(2~8個)の置換基R5-3が、結合しており、即ち、R5-2は、炭素数1~4の、4~10価の炭化水素基である。置換基R5-3は、炭化水素基の水素を置換するものである。また、R5-2としての、炭素数1~4の炭化水素基は、飽和であってもよいし、不飽和であってもよい。
R5-2が炭素数1の炭化水素基である場合(R5-2がN及びベンゼン環と共に4員環を形成する場合)、mは2であることが好ましい。炭素数1の4価の炭化水素基としては、メタン-テトライル基が挙げられる。
また、R5-2が炭素数2の炭化水素基である場合(R5-2がN及びベンゼン環と共に5員環を形成する場合)、mは2又は4であることが好ましい。この場合、R5-2は、飽和にも、不飽和にもなり得る。R5-2が飽和の場合、mは4であることが好ましく、R2-2が不飽和の場合、mは2であることが好ましい。炭素数2の4価の炭化水素基(炭素鎖)としては、エテン-テトライル基が挙げられ、炭素数2の6価の炭化水素基としては、エタン-ヘキサイル基が挙げられる。
また、R5-2が炭素数3の炭化水素基である場合(R5-2がN及びベンゼン環と共に六員環を形成する場合)、mは2、4又は6であることが好ましい。この場合、R5-2は、飽和にも、不飽和にもなり得る。R5-2が飽和の場合、mは6であることが好ましく、R5-2が不飽和の場合、mは4又は2であることが好ましい。炭素数3の4価の炭化水素基(炭素鎖)としては、プロピン-テトライル基が挙げられ、炭素数3の6価の炭化水素基(炭素鎖)としては、プロペン-ヘキサイル基が挙げられ、炭素数3の8価の炭化水素基(炭素鎖)としては、プロパン-オクタイル基が挙げられる。
また、R5-2が炭素数4の炭化水素基である場合(R5-2がN及びベンゼン環と共に七員環を形成する場合)、mは2、4、6又は8であることが好ましい。この場合、R5-2は、飽和にも、不飽和にもなり得る。R5-2が飽和の場合、mは8であることが好ましく、R5-2が不飽和の場合、mは6、4又は2であることが好ましい。炭素数4の6価の炭化水素基(炭素鎖)としては、ブタジエン-ヘキサイル基が挙げられ、炭素数4の8価の炭化水素基(炭素鎖)としては、ブテン-オクタイル基が挙げられ、炭素数4の10価の炭化水素基としては、ブタン-デカイル基が挙げられる。
また、上記一般式(2-5-1)中のR5-1は水素又はハロゲンであることが好ましく、水素又はフッ素であることが更に好ましい。一般式(2)中のR5が一般式(2-5-1)で表され、R5-1が水素又はハロゲンである場合、発光輝度が更に向上し、R5-1が水素又はフッ素である場合、発光輝度がより一層向上する。
R6に関して、炭素数1~3の炭化水素基としては、炭素数1~3のアルキル基、炭素数2~3のアルケニル基等が挙げられる。炭素数1~3のアルキル基としては、メチル基、エチル基、n-プロピル基、イソプロピル基が挙げられる。炭素数2~3のアルケニル基としては、ビニル基、アリル基等が挙げられる。
上記一般式(1)で表されるセレンテラジン誘導体は、特に限定されるものではないが、例えば、以下のようにして合成することができる。
(i-1)まず、2-アミノ-3,5-ジブロモアミノピラジンとベンジルマグネシウムクロリド及びビス(トリフェニルホスフィン)パラジウム(II)ジクロリドを用いたカップリング反応により、ベンジル体を合成する。
(i-2)次に、ベンジル体とボロン酸を用いて鈴木・宮浦カップリングを行い、6位に所望の環構造を導入したベンジル体を合成する。
(ii-1)或いは、2-アミノ-3,5-ジブロモアミノピラジンとボロン酸を用いて鈴木・宮浦カップリングを行い、フェニル体を合成する。
(ii-2)次に、フェニル体で再度鈴木・宮浦カップリングを行い、6位に所望の環構造を導入したフェニル体を合成する。
(iii)最後に、6位に所望の環構造を導入したベンジル体又はフェニル体をケトアセタール体と縮合環化反応させ、目的物質である一般式(1)で表されるセレンテラジン誘導体を合成することができる。
上記一般式(2)で表されるセレンテラジン誘導体は、特に限定されるものではないが、例えば、以下のようにして合成することができる。
(i)まず、2-アミノ-3,5-ジブロモアミノピラジンとボロン酸を用いて鈴木・宮浦カップリングを行い、6位に所望の環構造を導入した中間体を合成する。
(ii)NBSを用いてブロモ化させ、8位をブロモ化した中間体を合成する。
(iii)8位をブロモ化した中間体とチオールを水素化ナトリウムで置換反応を行い、チオール体を合成する。ここで、所望により、チオール体と三臭化ホウ素を反応させ、脱メチル化反応させてもよい。
(iv)最後に、チオール体をケトアセタール体と縮合環化反応させ、目的物質である一般式(2)で表されるセレンテラジン誘導体を合成することができる。
天然の発光酵素としては、ウミシイタケ(Renilla reniformis)由来のルシフェラーゼ(RLuc)、海洋性カイアシ(Gaussia princeps)由来のルシフェラーゼ(Gluc)、発光エビ(Oplophorus gracilirostris)由来のルシフェラーゼ(Oluc)、ウミサボテン由来のルシフェラーゼ等が挙げられる。
また、人工の発光酵素としては、発光エビ(Oplophorus gracilirostris)由来の人工の発光酵素であるPromega社製の「NanoLuc」、ウミシイタケ(Renilla reniformis)由来の人工の発光酵素であるRenillaルシフェラーゼ8.6-535SG(RLuc8.6SG)、産業技術総合研究所の金誠培博士らによって開発された発光プランクトン由来の人工発光酵素群であるALuc等が挙げられる。ここで、ALucには、種々の人工発光酵素があり、例えば、ALuc16、ALuc47、ALuc49等が挙げられる。
市販されている4-ベンジルオキシベンジルアルコール(3)(2g, 9.33 mmol)を乾燥ジクロロメタン(15 mL)に溶解させ、アルゴン雰囲気下、0℃で攪拌した。混合物に塩化チオニル(1.35 mL, 1.64 mmol)を加え、アルゴン雰囲気下、室温で2時間攪拌した。反応混合物に水を加えた後、ジクロロメタン(100 mL×3)で抽出した。抽出物を硫酸ナトリウムで乾燥させた後、減圧濃縮した。析出した固体をヘキサン洗浄し、化合物(4)を白色固体で得た(1.6 g, 6.84 mmol, 74 %)。
1H-NMR (500 MHz, CHLOROFORM-D) δ 7.43-7.37 (m, 4H), 7.34-7.33 (m, 1H), 7.31 (dd, J = 6.6, 2.0 Hz, 2H), 6.95 (dd, J = 6.6, 2.0 Hz, 2H), 5.07 (S, 2H), 4.56 (S, 2H)
1H-NMR (500 MHz, CHLOROFORM-D) δ 7.05 (dd, J = 11.5, 2.9 Hz, 2H), 6.75 (dd, J = 11.5, 3.4 Hz, 2H), 5.58 (S, 1H), 4.65 (S, 1H), 3.82 (S, 2H), 3.73-3.67 (m, 2H), 3.58-3.52 (m, 2H), 1.24 (t, J = 7.2 Hz, 6H)
HR-ESI-MS: m/z: [M+Na]+ C13H18Na1O4の計算値 261.11141; 実測値 261.11028
塩化亜鉛(2.7 g, 19.77 mmol)と1M ベンジルマグネシウムクロリド-テトラヒドロフラン溶液(22 mL, 19.77 mmol)をアルゴン雰囲気化で1時間攪拌した。この混合物に超脱水テトラヒドロフラン(22 mL)で溶解させたビス(トリフェニルホスフィン)パラジウム(II)ジクロリド(351 mg, 0.49 mmol)と、2-アミノ-3,5-ジブロモピラジン(6)(2.5 g, 9.89 mmol)を加え、4日間室温で攪拌した。反応混合物に水を加え、酢酸エチル(200 mL×3)で抽出した。抽出物を硫酸ナトリウムで乾燥させ、減圧濃縮した。残渣をシリカゲルクロマトグラフィー(w = 170 g, φ = 4.0 cm, ヘキサン:酢酸エチル = 4 : 1 → 3 : 1 )で精製し、化合物(7)を黄色油状で得た(2.1 g, 7.98 mmol, 81 %)。
1H-NMR (500 MHz, CHLOROFORM-D) δ 8.03 (s, 1H), 7.34-7.21 (m, 5H), 4.41 (s, 2H), 4.08 (s, 2H)
HR-ESI-MS: m/z: [M+H]+ C11H11 79Br1N3の計算値 264.01363; 実測値 264.01253
HR-ESI-MS: m/z: [M+H]+ C11H11 81Br1N3の計算値 266.01103; 実測値 266.01159
1H-NMR (500 MHz, ACETONE-D6) δ 8.35 (s, 1H), 7.48 (d, J = 2.3 Hz, 1H), 7.45 (dd, J = 8.3, 2.0 Hz, 1H), 7.37 (d, J = 8.0 Hz, 2H), 7.30 (t, J = 7.7 Hz, 2H), 7.21 (t, J = 7.4 Hz, 1H), 6.87 (d, J = 8.6 Hz, 1H), 5.54 (s, 1H), 4.29 (s, 4H), 4.16 (s, 2H)
HR-ESI-MS: m/z: [M+H]+ C19H18N3O2の計算値 320.13956; 実測値 320.13990
1H-NMR (500 MHz, METHANOL-D4, 0.5% TFA-D) δ 8.39 (s, 1H), 7.44 (d, J = 1.7 Hz, 1H), 7.41-7.38 (m, 3H), 7.32-7.29 (m, 2H), 7.26-7.23 (m, 1H), 7.10 (dd, J = 11.5, 2.9 Hz, 2H), 6.95 (d, J = 8.6 Hz, 1H), 6.73 (dd, J = 11.5, 2.9 Hz, 2H), 4.52 (s, 2H), 4.29 (m, 4H), 4.17 (s, 2H)
HR-ESI-MS: m/z: [M+H]+ C28H24N3O4の計算値 466.17655; 実測値 466.17668
市販されている2-アミノ-5-ジブロモピラジン(9)(2.0 g, 11.49 mmol)と市販されている4-メトキシフェニルボロン酸(2.6 g, 17.24 mmol)を1,4-ジオキサン(30 mL)に溶解し、簡易脱気した後、アルゴン雰囲気下にした。この混合物にテトラキス(トリフェニルホスフィン)パラジウム(0)(654 mg, 0.86 mmol)と、2 M炭酸ナトリウム水溶液(30 mL)を加え、110℃で1.5時間攪拌した。反応混合物を室温に戻した後、水を加え、酢酸エチル(200 mL×2)で抽出した。抽出物を硫酸ナトリウムで乾燥させた後、減圧濃縮した。残渣をシリカゲルクロマトグラフィーで(w = 100 g, φ = 4.0 cm, ヘキサン:酢酸エチル = 2 : 1 → 1 : 1)精製し、化合物(10)を薄黄色固体で得た(2.62 g, 13.03 mmol, 113 %)。
1H-NMR (500 MHz, CHLOROFORM-D) δ 8.40 (d, J = 1.7 Hz, 1H), 8.04 (d, J = 1.7 Hz, 1H), 7.81 (td, J = 6.0, 3.4 Hz, 2H), 6.98 (td, J = 6.0, 3.4 Hz, 2H), 4.54 (s, 2H), 3.86 (s, 3H)
HR-ESI-MS: m/z: [M+H]+ C16H14N3O1の計算値 202.09755; 実測値 202.09804
1H-NMR (500 MHz, CHLOROFORM-D) δ 8.34 (s, 1H), 7.81 (td, J = 6.0, 3.4 Hz, 2H), 6.97 (td, J = 6.0, 3.4 Hz, 2H), 4.99 (s, 2H), 3.85 (s, 3H)
HR-ESI-MS: m/z: [M+H]+ C11H11 79Br1N3O1の計算値 280.00907; 実測値 280.00855
HR-ESI-MS: m/z: [M+H]+ C11H11 81Br1N3O1の計算値 282.00530; 実測値 251.00650
1H-NMR (500 MHz, CHLOROFORM-D) δ 8.30 (s, 1H), 7.71 (dd, J = 6.6, 2.0 Hz, 2H), 7.49 (dd, J = 8.3, 1.4 Hz, 2H), 7.40-7.35 (m, 3H), 6.91 (dd, J = 6.9, 2.3 Hz, 2H), 4.84 (s, 2H), 3.83 (s, 3H)
HR-ESI-MS: m/z: [M+H]+ C17H16N3O1S1の計算値 310.10158; 実測値 310.10141
1H-NMR (500 MHz, ACETONE-D6) δ 8.31 (s, 1H), 7.64 (dd, J = 6.9, 2.3 Hz, 2H), 7.51 (dt, J = 8.2, 1.9 Hz, 2H), 7.42-7.35 (m, 3H), 6.80 (dd, J = 6.6, 2.0 Hz, 2H), 5.75 (s, 2H)
HR-ESI-MS: m/z: [M+H]+ C16H14N3O1S1の計算値 296.08613; 実測値 296.08576
1H-NMR (500 MHz, METHANOL-D4) δ 8.16 (s, 1H), 7.66 (dd, J = 7.2, 2.0 Hz, 2H), 7.53-7.49 (m, 5H), 7.11 (d, J = 8.6 Hz, 2H), 6.72 (d, J = 4.6 Hz, 2H), 6.70 (d, J = 4.0 Hz, 2H), 4.03 (s, 2H)
HR-ESI-MS: m/z: [M+H]+ C25H20N3O3S1の計算値 442.12153; 実測値 442.12254
構造式(2-1)で表される化合物の合成の項と同様にして、化合物(11)を合成した。
1H-NMR (500 MHz, CHLOROFORM-D) δ 8.26 (s, 1H), 7.65 (dd, J = 6.9, 2.3 Hz, 2H), 7.54-7.51 (m, 2H), 7.12-7.08 (m, 2H), 6.89 (dd, J = 6.9, 1.7 Hz, 2H), 4.89 (s, 2H), 3.82 (s, 3H)
HR-ESI-MS: m/z: [M+H]+ C17H15F1N3O1S1の計算値 328.09432; 実測値 328.09199
1H-NMR (500 MHz, METHANOL-D4) δ 8.15 (s, 1H), 7.57 (td, J = 5.9, 2.5 Hz, 2H), 7.50 (dd, J = 6.6, 2.0 Hz, 2H), 7.20-7.16 (m, 2H), 6.73 (dd, J = 6.6, 2.0 Hz, 2H)
HR-ESI-MS: m/z: [M+H]+ C16H13F1N3O1S1の計算値 314.07754; 実測値 314.07634
1H-NMR (500 MHz, METHANOL-D4) δ 8.10 (s, 1H), 7.65 (qd, J = 5.7, 3.0 Hz, 2H), 7.46 (dd, J = 6.9, 2.3 Hz, 2H), 7.24-7.21 (m, 2H), 7.10 (d, J = 8.0 Hz, 2H), 6.71 (d, J = 8.6 Hz, 2H), 6.69 (dd, J = 6.6, 2.0 Hz, 2H), 4.02 (s, 2H)
HR-ESI-MS: m/z: [M+H]+ C25H19F1N3O3S1の計算値 460.11304; 実測値 460.11311
構造式(1-1)で表される化合物の合成の項と同様にして、化合物(7)を合成した。
1,4-ベンゾジオキサン-6-ボロン酸に代えて、3-ピリジルボロン酸を使用し、構造式(1-1)で表される化合物の合成と同様にして、比較化合物(17)を合成した。
以下に反応スキームを示す。
1H-NMR (500 MHz, METHANOL-D4) δ 8.96 (s, 1H), 8.57 (dd, J = 4.9, 1.4 Hz, 1H), 8.21 (d, J = 8.0 Hz, 1H), 8.06 (s, 1H), 7.52 (dd, J = 8.0, 5.2 Hz, 1H), 7.39 (d, J = 7.4 Hz, 2H), 7.28 (t, J = 7.4 Hz, 2H), 7.22-7.19 (m, 1H), 7.13 (d, J = 8.6 Hz, 2H), 6.69 (d, J = 8.6 Hz, 2H), 4.41 (s, 2H), 4.07 (s, 2H)
HR-ESI-MS: m/z: [M+H]+ C25H21N4O2の計算値 409.16635; 実測値 409.16645
構造式(1-1)で表される化合物の合成の項と同様にして、化合物(7)を合成した。
1,4-ベンゾジオキサン-6-ボロン酸に代えて、4-ピリジルボロン酸を使用し、構造式(1-1)で表される化合物の合成と同様にして、比較化合物(19)を合成した。
以下に反応スキームを示す。
1H-NMR (500 MHz, METHANOL-D4) δ 9.17 (s, 1H), 8.90 (d, J = 6.9 Hz, 2H), 8.72 (d, J = 6.9 Hz, 2H), 7.42 (d, J = 6.9 Hz, 2H), 7.31-7.28 (m, 2H), 7.24-7.21 (m, 1H), 7.11 (dd, J = 11.5, 2.9 Hz, 2H), 6.71 (dd, J = 6.6, 2.0 Hz, 2H), 4.55 (s, 2H), 4.17 (s, 2H)
HR-ESI-MS: m/z: [M+H]+ C25H21N4O2の計算値 409.16614; 実測値 409.16645
ベンジルマグネシウムクロリドに代えて、フェニルボロン酸を使用し、また、1,4-ベンゾジオキサン-6-ボロン酸に代えて、4-ヒドロキシボロン酸を使用し、構造式(1-1)で表される化合物の合成と同様にして、比較化合物(22)を合成した。
以下に反応スキームを示す。
1H-NMR (500 MHz, METHANOL-D4) δ 8.01 (d, J = 5.2 Hz, 2H), 7.65 (s, 1H), 7.60-7.55 (m, 3H), 7.13 (d, J = 8.6 Hz, 2H), 6.90 (dd, J = 6.6, 2.0 Hz, 2H), 6.66 (dd, J = 6.6, 2.0 Hz, 2H), 4.03 (s, 2H)
HR-ESI-MS: m/z: [M+H]+ C25H20N3O3の計算値 410.14906; 実測値 410.15047
ATTO株式会社製発光スペクトル装置AB-1850を用いて測定した。
測定したスペクトルは全て検出器の特性を補正したスペクトルである。
発光測定には、PerkinElmer社製IVISイメージングシステム(Caliper Life Sciences)を用いた。
また、発光酵素を発現する生細胞(Live cells)としては、アフリカミドリザル腎臓由来のCOS-7細胞を使用し、また、該生細胞を溶解したライセート(Lysate)でも評価した。
アフリカミドリザル腎臓由来のCOS-7細胞を6穴マイクロプレートに植え、70%の底面積を埋めるほど生えた時点までCO2インキュベーターで培養する。TransIT-LT1試薬(Mirus)を用いて各ウェル細胞に、以下の海洋生物由来の各発光酵素をコードするプラスミドを一過性発現させる。
(i)ALuc16
(ii)ALuc47
(iii)Renillaルシフェラーゼ8.6-535SG(RLuc8.6SG)
(iv)NanoLuc
このリポフェクション後、1日間、CO2インキュベーターで継続培養する。それから、各細胞を96穴マイクロプレートにサブカルチャーし、更に1日間培養する。
結果を図1、図2、図4、図5、図7、図8、図10及び図11に示す。図1、図2、図4、図5、図7、図8、図10及び図11中、構造式(1-1)で表される化合物を「(1-1)」と表記し、構造式(2-1)で表される化合物を「(2-1)」と表記し、構造式(2-2)で表される化合物を「(2-2)」と表記し、比較化合物(17)を「(17)」と表記し、比較化合物(19)を「(19)」と表記し、比較化合物(22)を「(22)」と表記した。
COS-7細胞を6穴マイクロプレートに植え、70%の底面積を埋めるほど生えた時点までCO2インキュベーターで培養する。TransIT-LT1試薬(Mirus)を用いて各ウェル細胞に、以下の海洋生物由来の各発光酵素をコードするプラスミドを一過性発現させる。
(i)ALuc16
(ii)ALuc47
(iii)Renillaルシフェラーゼ8.6-535SG(RLuc8.6SG)
(iv)NanoLuc
このリポフェクション後、1日間、CO2インキュベーターで継続培養する。6穴マイクロプレートの細胞培地を完全に除去した後、各ウェルにPromega製の細胞溶解試薬(ライセート)を200μLずつ加え、15分間室温でインキュベーションする。
このライセート20μLをPCRチューブにそれぞれ分注し、発光輝度評価時の100μM希釈発光基質溶液20μL添加した。PCRチューブを直ちに分光光度計(AB-1850、ATTO)に入れ、高感度モードの0.5秒、5秒、10秒、30秒の積算モードより生物発光スペクトルを測定した。
結果を図3、図6、図9及び図12に示す。図3、図6、図9及び図12中、構造式(1-1)で表される化合物を「(1-1)」と表記し、構造式(2-1)で表される化合物を「(2-1)」と表記し、構造式(2-2)で表される化合物を「(2-2)」と表記した。
図1及び図2から分かるように、構造式(1-1)で表される化合物は、ALuc16に対して高輝度で発光を示した。また、図4、図5、図7及び図8から分かるように、構造式(1-1)で表される化合物は、ALuc47及びRLuc8.6SGに対して僅かに発光を示した。一方、図10及び図11から分かるように、構造式(1-1)で表される化合物は、NanoLucに対しても発光活性を示さなかった。
このように、構造式(1-1)で表される化合物は、ALuc16に酵素特異性を有することが確認された。
また、図1、図2、図7及び図8から分かるように、構造式(2-2)で表される化合物は、ALuc16、RLuc8.6SGに対して発光活性を示し、図4、図10及び図11から分かるように、ALuc47及びNanoLucに対して僅かに発光を示した。
このように、構造式(2-1)又は(2-2)で表される化合物も、酵素特異性を有することが確認された。
また、構造式(2-1)又は(2-2)で表される化合物は、天然のセランテラジン等に比べて、発光波長が50nm程度長波長化することが確認された。
Claims (9)
- 下記一般式(1):
[一般式(1)中、R1は、下記一般式(1-1-1)、(1-1-2)、(1-1-3)又は(1-1-4):
で表され、ここで、R1-1は、炭素数1~4の炭化水素基であり、R1-2は、それぞれ独立して水素又は炭素数1~3の炭化水素基であり、mは、2~8の整数であり、
R2は、-R2’又は-CH2-R2’で表され、ここで、R2’は、下記一般式(1-2-1)、(1-2-2)、(1-2-3)、(1-2-4)又は(1-2-5):
で表され、ここで、R2-1は、水素、ハロゲン、-N(R2-1-1)2又は-OR2-1-1であり(ここで、R2-1-1は、それぞれ独立して水素又は炭素数1~3の炭化水素基である。)、R2-2は、炭素数1~4の炭化水素基であり、R2-3は、それぞれ独立して水素又は炭素数1~3の炭化水素基であり、mは、2~8の整数であり、
R3は、下記一般式(1-3-1)、(1-3-2)又は(1-3-3):
で表され、ここで、R3-1は、水素又は炭素数1~3の炭化水素基である。]、又は、
下記一般式(2):
[一般式(2)中、R4は、水素、-(CH2)n-OR4-1、-N(R4-1)2又は-CF3であり、ここで、R4-1は、それぞれ独立して水素又は炭素数1~3の炭化水素基であり、nは、0~3の整数であり、
R5は、下記一般式(2-5-1)、(2-5-2)、(2-5-3)、(2-5-4)又は(2-5-5):
で表され、ここで、R5-1は、水素、ハロゲン、-N(R5-1-1)2又は-OHであり(ここで、R5-1-1は、それぞれ独立して水素又は炭素数1~3の炭化水素基である。)、R5-2は、炭素数1~4の炭化水素基であり、R5-3は、それぞれ独立して水素又は炭素数1~3の炭化水素基であり、mは、2~8の整数であり、
R6は、水素又は炭素数1~3の炭化水素基である。]で表されることを特徴とする、セレンテラジン誘導体。 - 上記一般式(1)で表され、
R1が、上記一般式(1-1-3)で表される、請求項1に記載のセレンテラジン誘導体。 - 上記一般式(1)で表され、
R2が、-CH2-R2’で表され、ここで、R2’が、上記一般式(1-2-1)で表される、請求項1又は2に記載のセレンテラジン誘導体。 - 上記一般式(1)で表され、
R3が、上記一般式(1-3-2)で表される、請求項1~3のいずれか一項に記載のセレンテラジン誘導体。 - 上記一般式(2)で表され、
R4が、-(CH2)n-OR4-1で表される、請求項1に記載のセレンテラジン誘導体。 - 上記一般式(2)で表され、
R5が、上記一般式(2-5-1)で表される、請求項1又は6に記載のセレンテラジン誘導体。 - 上記一般式(2)で表され、
R6が、水素である、請求項1、6及び7のいずれか一項に記載のセレンテラジン誘導体。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18/841,467 US20250171450A1 (en) | 2022-02-28 | 2023-02-21 | Novel coelenterazine derivatives |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022-030488 | 2022-02-28 | ||
| JP2022030488 | 2022-02-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2023162995A1 true WO2023162995A1 (ja) | 2023-08-31 |
Family
ID=87765962
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/JP2023/006307 Ceased WO2023162995A1 (ja) | 2022-02-28 | 2023-02-21 | 新規セレンテラジン誘導体 |
Country Status (3)
| Country | Link |
|---|---|
| US (1) | US20250171450A1 (ja) |
| JP (1) | JP2023126161A (ja) |
| WO (1) | WO2023162995A1 (ja) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011007314A1 (en) * | 2009-07-13 | 2011-01-20 | Università Degli Studi Di Siena | IMIDAZO[1,2-α]PYRAZIN-3(7H)-ONE DERIVATIVES BEARING A NEW ELECTRON-RICH STRUCTURE |
| CN105968114A (zh) * | 2016-05-27 | 2016-09-28 | 山东大学 | 一种腔肠素类似物及其制备方法与应用 |
| JP2018165265A (ja) * | 2017-03-28 | 2018-10-25 | 国立大学法人電気通信大学 | 新規セレンテラジン誘導体 |
| JP2019524763A (ja) * | 2016-07-28 | 2019-09-05 | プロメガ コーポレイションPromega Corporation | セレンテラジン類縁体 |
| CN111116594A (zh) * | 2019-12-03 | 2020-05-08 | 山东大学 | 一种C-6位改造NanoLuc类型类似物及其制备方法与应用 |
-
2023
- 2023-02-21 JP JP2023025582A patent/JP2023126161A/ja active Pending
- 2023-02-21 WO PCT/JP2023/006307 patent/WO2023162995A1/ja not_active Ceased
- 2023-02-21 US US18/841,467 patent/US20250171450A1/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011007314A1 (en) * | 2009-07-13 | 2011-01-20 | Università Degli Studi Di Siena | IMIDAZO[1,2-α]PYRAZIN-3(7H)-ONE DERIVATIVES BEARING A NEW ELECTRON-RICH STRUCTURE |
| CN105968114A (zh) * | 2016-05-27 | 2016-09-28 | 山东大学 | 一种腔肠素类似物及其制备方法与应用 |
| JP2019524763A (ja) * | 2016-07-28 | 2019-09-05 | プロメガ コーポレイションPromega Corporation | セレンテラジン類縁体 |
| JP2018165265A (ja) * | 2017-03-28 | 2018-10-25 | 国立大学法人電気通信大学 | 新規セレンテラジン誘導体 |
| CN111116594A (zh) * | 2019-12-03 | 2020-05-08 | 山东大学 | 一种C-6位改造NanoLuc类型类似物及其制备方法与应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023126161A (ja) | 2023-09-07 |
| US20250171450A1 (en) | 2025-05-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5582505B2 (ja) | セレンテラジン類縁体及びその製造方法 | |
| Kele et al. | Clickable fluorophores for biological labeling—with or without copper | |
| Wang et al. | A general approach to spirolactonized Si-rhodamines | |
| Liu et al. | A novel near-infrared fluorescent platform with good photostability and the application for a reaction-based Cu2+ probe in living cells | |
| JP2016050296A (ja) | 蛍光色素結合セレンテラジン | |
| JP5550035B2 (ja) | 波長が制御されたルシフェラーゼの発光基質および製造方法 | |
| WO2009096197A1 (ja) | ルシフェラーゼの発光基質 | |
| Zhang et al. | A profluorescent ratiometric probe for intracellular pH imaging | |
| EP1731898A1 (en) | Fluorescent probes | |
| JP2010215795A5 (ja) | ||
| WO2007105529A1 (ja) | 化学発光性化合物及びそれから成る標識剤 | |
| CN112920095B (zh) | 新型聚集诱导发光内质网荧光探针及其制备方法与应用 | |
| CN105330635A (zh) | 色原酮类衍生物和作为荧光染料的用途 | |
| JP5585960B2 (ja) | チオールの検出方法 | |
| JP7204728B2 (ja) | 血清中で安定なプロセレンテラジン類似体 | |
| WO2023162995A1 (ja) | 新規セレンテラジン誘導体 | |
| CN112851556B (zh) | 新型聚集诱导发光高尔基体荧光探针及其制备方法与应用 | |
| JP2023007068A (ja) | 蛍光色素、蛍光色素で標識された生体分子、及び化合物又はその塩 | |
| JP2009014369A (ja) | 生体分子標識用蛍光試薬 | |
| CN106634964A (zh) | 噁嗪类化合物在制备近红外荧光探针中的应用 | |
| WO2019168199A1 (ja) | カルボキシペプチダーゼ活性検出用蛍光プローブ | |
| CN114989068B (zh) | 一种可调控电子密度的硫化氢响应荧光探针及其制备工艺与应用 | |
| JP7713216B2 (ja) | 新規複素環式化合物及びその塩、並びに、発光基質組成物 | |
| JP7255828B2 (ja) | 新規複素環式化合物及びその塩、並びに、発光基質組成物 | |
| Heinrich | Chemical Biology Applications of Photoresponsive DNA-Binding Agents |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23758214 Country of ref document: EP Kind code of ref document: A1 |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 18841467 Country of ref document: US |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 23758214 Country of ref document: EP Kind code of ref document: A1 |
|
| WWP | Wipo information: published in national office |
Ref document number: 18841467 Country of ref document: US |








































